Skip to main content

Table 1 Patient and treatment characteristics

From: Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma

Parameter

Nr

A. Patient and tumor characteristics

Age (years) Median (range)

67 (36-87)

Gender

 Male

24 (56%)

 Female

19 (44%)

Tumor location a

 IHCC

17 (40%)

 EHCC

26 (60%)

Treatment

 Primary inoperable

26 (70%)

 Recurrent

8 (22%)

 Positive margins

3 (08%)

Prior therapies

 Resection

12 (32%)

 Chemotherapy

6 (16%)

  Gemcitabine/Oxaliplatin

1

  Gemcitabine

1

  Capecitabin

1

  5-FU

1

Therapies after SBRT

 Chemotherapy

13 (35%)

 TACE

1 (03%)

CA 19-9 (U/ml) Median (IQR)

149 (20-499)

Bilirubin (mg/dl) Median (range)

0.8 (0.5-21)

GTV Diameter (cm)a Median (IQR)

4.9 (3.4-8.2)

PTV Volume (cm3)a Median (IQR)

124 (60-329)

B. Treatment characteristics

Prescribed dose (Gy)a

 Median (IQR)

45 (38-48)

 Maximum point dose (Gy)a

 Median (IQR)

51 (44-58)

 Mean PTV dose (Gy)a

 Median (IQR)

47 (42-51)

 EQD210 (Gy)a

 Median (IQR)

56 (47-61)

EQD210 Maximum point dose (Gy)

 Median (IQR)

65 (59-85)

EQD210 Mean dose (Gy)

 Median (IQR)

63 (53-82)

  1. IHCC Intrahepatic cholangiocarcinoma, EHCC Extrahepatic cholangiocarcinoma, 5-FU 5-Fluoruracil, IQR interquartile range, EQD2 equieffective doses in 2 Gy (α/β = 10)
  2. aper lesion